Calton & Associates’s Travere Therapeutics TVTX Stock Holding History

Calton & Associates’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-9,608	Closed	-$298K	–	409
2021 Q4	$298K	Sell	9,608 -168	-2%	-$4.73K	0.08%	260
2021 Q3	$237K	Buy	+9,776	New	+$180K	0.05%	340
2021 Q2	–	Sell	-10,098	Closed	-$252K	–	429
2021 Q1	$252K	Buy	10,098 +13	+0.1%	+$359	0.05%	321
2020 Q4	$275K	Sell	10,085 -368	-4%	-$8.59K	0.05%	285
2020 Q3	$193K	Sell	10,453 -317	-3%	-$6.16K	0.04%	321
2020 Q2	$220K	Sell	10,770 -63	-0.6%	-$1K	0.05%	281
2020 Q1	$158K	Buy	+10,833	New	+$163K	0.04%	277

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Calton & Associates's TVTX Position: Q1 2022 in Review

Calton & Associates sold out of Travere Therapeutics (TVTX) in Q1 2022, closing a stake of 9,608 shares — an estimated $298K sold.

Calton & Associates first reported a position in TVTX in Q1 2020 and held it in 7 quarters. The position peaked at $298K in Q4 2021. 169 funds tracked by Wall St. Rank hold TVTX as of Q1 2022.

Calton & Associates reported no remaining Travere Therapeutics position as of Q1 2022 after selling out during the quarter.
Calton & Associates sold 9,608 Travere Therapeutics shares in Q1 2022, an estimated $298K.
Calton & Associates first reported a position in Travere Therapeutics in Q1 2020 and held it in 7 quarters.
Calton & Associates's Travere Therapeutics position peaked at $298K in Q4 2021.
169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2022.

Based on Calton & Associates's 13F filing for Q1 2022, filed 12 Apr 2022.